Today: November 25, 2015, 5:21 pm

Global kidney cancer drugs market: 13% CAGR between 2012-2016
Global Kidney Cancer Drugs Market 2012-2016 - a new market research report on 2014-03-05 15:31:03
The Global Kidney Cancer Drugs market is to grow at a CAGR of 13.4 percent over the period 2012-2016. One of the key factors contributing to this market growth is the growing demand in developing economies. The Global Kidney Cancer Drugs market has also been witnessing an increase in R&D activities. However, over-dependence of the market on the US could pose a challenge to the growth of this market.

The vendors in this market are investing heavily in R&D to develop kidney cancer drugs from biological sources because this approach can increase the efficacy of the drugs. Moreover, vendors are formulating effective injection solutions that can help retain the efficacy of the drug molecule for a longer period. For instance, Pfizer Inc. is increasingly focusing on enhancing the efficacy of its kidney cancer drug Sutent. Moreover, vendors are increasing their investment in the R&D of drugs that can be used for the treatment of more than one type of cancer.

The US government has increased expenditure on healthcare because of the prevalence of several diseases, which are largely due to the changing lifestyles of individuals, environmental health hazards, and genetic disorders. As a result, the use of therapeutic drugs for the treatment of cancer has increased. Healthcare spending in the US has increased significantly. Thus, the opportunity for revenue generation has increased, which acts as a driver of the Kidney Cancer Drugs market in the US. Moreover, this increase in healthcare expenditure is expected to increase the quality of treatments as well as the number of R and D projects. This is one of the major drivers contributing to the growth of the Global Kidney Cancer Drugs market.

The key vendors dominating this market space are AVEO Pharmaceuticals Inc., Bayer AG, GlaxoSmithKline plc, Hoffmann-La Roche Ltd., Novartis AG, and Pfizer Inc. The other vendors mentioned in the report are AstraZeneca plc, Onyx Pharmaceuticals Inc., Merck Serono S.A., and WILEX AG.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600

# 530 Words
Related Articles
More From Finance
USGFX Anticipates A Rise In Forex Trading [..]
The Shanghai Composite Index has been volatile and at one stage dropped more than 30% from its June 12 peak, [..]
Credit-Yogi Recommends Reputable Debt Solution Companies To [..]
Many people who have poor credit don’t know what to do about it. They realize that their bad credit prevents [..]
Credit-Yogi Reveals Special Considerations for Military Members [..]
No one wants to have their vehicle taken back by their banks. It’s a source of stress for the individual [..]
Credit-Yogi Teaches Consumers How To Use HAMP [..]
Be Prepared to Utilize HAMP Lenders do not like to help borrowers prevent foreclosure by accessing the Obama loan modification [..]
Credit-Yogi Informs Military Members Facing Auto Repossession [..]
No one wants to have their vehicle taken back by their banks. It’s a source of stress for the individual [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.